Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive, HER2-negative status confers therapeutic sensitivity to Fulvestrant in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Canada:
FASLODEX (fulvestrant) is indicated for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.